Corey J. Langer, MD:EGFRmutations are present in about 10% to 15% of the newly diagnosed nonsmall cell North American population. If we look at East Asia, specifically at a person of East Asian ethnicity, who is a never-smoker female with adenocarcinoma, the likelihood of having anEGFRmutation goes up to 60% to 65%. So, it’s imperative, in the modern era of personalized medicine, specifically personalized oncology, that we work up our patients forEGFR.
In my own clinic, I would guesstimate that I have at least 60 or 70 patients withEGFRmutations. The vast majority are doing quite well. They’re on a variety of tyrosine kinase inhibitors (what we call TKIs). Some of them are on TKIs for several years. In fact, one of my patients who was on one of the original gefitinib trials remains on the agentnow going on a decade and a half. So, 15 to 16 years with metastatic lung cancer to bone.
This population does far better than the general nonsmall cell lung cancer population. If we look at older studies, on average, their median survival is 2.5 to 3 years. With more modern treatment, I’d venture to guess that we’re doing even better than that. Many of these patients are living 4, 5, or 6 years or longer.
Of all the actionable mutations that exist,EGFRis the most common. It is not the most common mutation, however.KRASmutations are found in 25% to 35% of newly diagnosed nonsmall cell, nonsquamous patients. Unfortunately, we don’t yet have a drug or a TKI for that group.KRASis much more commonly seen in smokers or former smokers, whereasEGFRmutations are typically seen in never-smokers or remote former smokers. My rule of thumb, regarding the workup forEGFR, is to test all patients with adenocarcinoma, regardless of smoking history, and all never-smokers or remote former smokers, regardless of histology.
Transcript edited for clarity.
June 2017
March 2018
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More